drugset
drugset / Trial / NCT06595797

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome

NCT06595797 ↗

Phase 2 Not yet recruiting 144 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects

Timeline

Start
2024-09
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown — —

Indications

polycystic ovary syndrome